KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study.

Christina Charles-Schoeman, Joachim Schessl, Zsuzsanna Bata-Csörgő, Mazen M Dimachkie, Zoltan Griger, Sergey Moiseev, Chester V Oddis, Elena Schiopu, Jiri Vencovský, Elisabeth Clodi, Todd Levine, Rohit Aggarwal

Rheumatology (Oxford) 64(6) 3767-3776

PMID39918968
PMCIDPMC12107041
DOI10.1093/rheumatology/keaf070
发表日期2025-02-07
入排依据:未发现恶性肿瘤人群证据。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。
摘要

摘要

OBJECTIVES: The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM. METHODS: ProDERM was a prospective, randomized, placebo-controlled study of DM patients. For weeks 0-16, patients received 2.0 g/kg IVIg (Octagam, 10%) or placebo every 4 weeks. Eligible patients entered the open-label extension phase, where all received IVIg to week 40. Univariate and multivariate analyses examined associations between baseline variables and total improvement score (TIS), including myositis disease activity assessment tool (MDAAT; assessing different organ involvement), and myositis-specific and myositis-associated autoantibodies. RESULTS: Ninety-five patients were enrolled. Univariate analyses found no significant association between TIS at week 16 or 40 and age; sex; ethnicity; disease duration/activity; cutaneous, skeletal, gastrointestinal or muscle disease activity; or previous failed or concomitant medications. Multivariate analysis found patients with higher MDAAT cutaneous scores had a better chance of at least minimal TIS improvement. Higher MDAAT pulmonary scores were associated with a lower, but still considerable, chance of improvement. Patients with TIF1-γ antibodies had a better TIS response; however, after controlling for cutaneous disease activity, there was no significant association between antibody classification (including anti-TIF1-γ) and efficacy outcome. CONCLUSION: IVIg was effective in treating DM patients regardless of demographic features and autoantibody status (for most autoantibodies). Patients with higher cutaneous disease activity and/or anti-TIF1-γ responded best to IVIg, while pulmonary disease activity predicted a lower, but still effective, IVIg response, warranting further investigation. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02728752.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Numbers of dermatomyositis patients with myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) ( n = 95). Patients may have been positive for more than one autoantibody type and therefore the percentage of patients totals more than 100%. All patients in the study were negative for the following autoantibodies: PL-7, OJ, EJ, U2 RNP, U3 RNP, RNA-Pol, KS, FER, MiTO, RIBO-P and U5 RNP. a No relevant autoantibodies detected. MAA: myositis-associated antibodies; MSA: myositis-specific antibodies
非 KM Figure